News and Announcements
Shivom Covered on David Pakman Show, Finance News Network, and ICO review
- Published April 10, 2018 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Key Takeaways:
- Shivom featured on the Finance News Network, David Pakman Show, and ICO Review
- Shivom generates a traction through its futuristic interlocking of blockchain technology and genomic data.
Shivom is creating a lot of buzz with its unique and futuristic interlocking of blockchain technology and genomic data. Recently, Shivom’s CEO Axel Schumacher and CIO Henry Ines have been featured on the Finance News Network, David Pakman Show, and ICO Review.
The videos offer insights on the project, Shivom’s ICO offering, and include interviews with Co-Founders of Shivom and their vision, respectively.
You can view the videos at:
ICO Review – https://youtu.be/u62-J7QWpMA
David Pakman show featuring Henry Ines – https://www.youtube.com/watch?
Finance News Network featuring Dr. Axel Schumacher and Henry Ines –https://www.youtube.com/watch?
These videos highlight Shivom’s prospects and its purpose of decentralising DNA and genomic data while ensuring full control and privacy to the DNA donors and genomic data providers.
Watch the Co-founding team talk to experts and explain the idea behind Shivom’s creation as they also provide a perspective on the future of precision medicine, DNA-based medical research, blockchain solutions and the importance of encrypting sensitive information DNA. In these videos, they also address concerns surrounding Shivom’s proposed use of the blockchain technology and genomic information.
We would also like to inform you that we are nearing the crowd sale event of our OmiX token which is only a few days from now.
About Shivom
Shivom combines blockchain, A.I., DNA sequencing & cryptography to enable secure and personalized medicine. The Shivom platform works on collaboration & integrity, allowing people to own, manage and monetize their data. By creating a web-marketplace, a network of genomic counsellors, and a not-for-profit drug research unit, Shivom will build a global healthcare ecosystem, reaching even low-income countries.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
